The Medical Technology Blog

Medtronic boosts AF market presence with Health Canada approval

Welcome back to the Medical Technology Blog. Once again i have to apologise for the lack of posts recently, but i am currently updating our main website Espicom, with 60+ pages of world pharmaceutical market pages as well as many new reports, which i will list in my next post, thank you for your patience, please read on…

In a move that brings Medtronic one step closer to securing its goal of becoming the physician partner of choice for atrial fibrillation (AF) ablation, the company has welcomed news of Health Canada approval for its Ablation Frontiers Cardiac Ablation System.

Ablation Frontiers’ radiofrequency (RF) ablation technology for the treatment of AF was added to Medtronic’s growing AF Solutions franchise in February 2009 when the company acquired Ablation Frontiers for US$225 million. Operating within Medtronic’s Cardiac Rhythm Disease Management (CRDM) business, Ablation Frontiers, alongside CryoCath Technologies, a leader in cryoablation treatments for AF which was acquired by Medtronic in November 2008, expand the company’s AF Solutions business. The goal of Medtronic’s AF Solutions franchise is to be the physician partner of choice for AF ablation by bringing breakthrough AF therapies to patients and physicians that are simpler, safer, and offer more predictable procedure times than current treatment methods.

With this latest receipt of Health Canada approval, it would seem that Medtronic is now well positioned to address the increasingly significant area of AF with its Ablation Frontiers Cardiac Ablation System tools now approved for use in Canada, which include the GENius multi-channel RF generator and the Pulmonary Vein Ablation Catheter (PVAC), a single anatomically-shaped mapping and ablation catheter designed to efficiently isolate the pulmonary veins to treat AF. The GENius generator and PVAC, with the addition of the Multi-Array Septal Catheter (MASC) and Multi-Array Ablation Catheter (MAAC), are available in Europe and are under investigational use in the US. As a condition of Health Canada’s approval, Medtronic will provide periodic clinical updates on the safety and effectiveness of the PVAC catheter.

Going forward, Medtronic’s previous acquisition of Ablation Frontiers and CryoCath Technologies is set to further expand the company’s presence in the AF market with additional product milestones expected to take place in the near future. These include the anticipated receipt of FDA approval for the Medtronic Arctic Front Cardiac CryoAblation Catheter System, for which a PMA was submitted in March 2010, and gaining FDA approval for Ablation Frontiers’ system of catheters and the RF generator for permanent, or chronic, AF.

Please check back soon for an updated list of new reports at Espicom Business Intelligence, thanks, Paul.



Espicom Business Intelligence

Tagged with:

Filed under: Company NewsMedical Technology

Like this post? Subscribe to my RSS feed and get loads more!